Stockreport

Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305

LOXO ONCOLOGY  (LOXO) 
Last loxo oncology earnings: 11/8 06:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.loxooncology.com
PDF STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the development and commercialization of h [Read more]